Floatz logo

Dasatinib

Anemia

OHSU Knight Cancer InstituteSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Anemia cohort.

Asset / SponsorPhaseRating
Epoetin Alfa
Mayo Clinic
Phase 4BBB
Erythropoietin Human Recombinant
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Epoetin Beta
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4BBB
Cyclophosphamide
OHSU Knight Cancer Institute
Phase 4BBB

View all 50 →

Same molecule, other indications

Dasatinib is also rated in:

B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →
chronic myeloid leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →